<qa>  What is the potential single dose radical cure treatment for patients with Plasmodium vivaThe study aims to provide evidence of retinal safety to support the use of tafenoquine as a potential single dose radical cure treatment for patients with Plasmodium vivax P. vivax malaria i.e., co-administration of a schizonticidal drug with TQ. The study will be conducted as a single masked, randomized, placebo-controlled, parallel group design. It will assess retinal changes from baseline using spectral domain optical coherence tomography OCT and fundus auto fluorescence FAF at Month 3 90 days post-dose in adult healthy volunteers participants. A placebo control group will be used to compare the results in the TQ group. Interim analysis will be conducted after completing 100 out of 300 participants in TQ group and 50 out of 150 participants in matched placebo. 